-- MediSwitch Drug Interactions Import (Part 106/112)
INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(4437, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(4437, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(4437, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(4437, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(4437, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(4437, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26118, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26118, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26118, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26118, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26118, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26118, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26118, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26118, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26118, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26118, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26118, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26118, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26118, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26118, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26118, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26118, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26118, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26118, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26118, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26118, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26118, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26118, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26118, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26118, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(25087, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(25087, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(25087, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25087, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(25087, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(25087, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25087, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(25087, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25087, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(25087, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(25087, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25087, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(25087, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(25087, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(25087, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(25087, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(25087, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25087, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(25087, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(25087, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(25087, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(25087, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25087, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(25087, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(14405, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(14405, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(14405, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(14405, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(14405, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(14405, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(14405, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(14405, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(14405, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(14405, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(14405, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(14405, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(14405, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(14405, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(14405, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(14405, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(14405, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(14405, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(14405, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(14405, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(14405, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(14405, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(14405, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(14405, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26116, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26116, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26116, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26116, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26116, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26116, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26116, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26116, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26116, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26116, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26116, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26116, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26116, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26116, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26116, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26116, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26116, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26116, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26116, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26116, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26116, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26116, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26116, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26116, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(23294, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(23294, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(23294, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(23294, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(23294, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(23294, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(23294, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(23294, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(23294, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(23294, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(23294, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(23294, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(23294, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(23294, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(23294, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(23294, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(23294, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(23294, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(23294, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(23294, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(23294, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(23294, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(23294, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(23294, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(20255, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(20255, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(20255, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(20255, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(20255, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(20255, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(20255, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(20255, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(20255, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(20255, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(20255, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(20255, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(20255, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(20255, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(20255, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(20255, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(20255, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(20255, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(20255, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(20255, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(20255, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(25084, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(25084, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(25084, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25084, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(25084, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(25084, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25084, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(25084, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25084, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(25084, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(25084, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25084, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(25084, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(25084, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(25084, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(25084, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(25084, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25084, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(25084, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(25084, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(25084, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(25084, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25084, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(25084, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26129, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26129, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26129, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26129, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26129, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26129, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26129, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26129, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26129, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26129, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26129, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26129, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26129, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26129, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26129, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26129, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26129, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26129, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26129, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26129, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26129, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26129, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26129, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26129, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26148, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26148, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26148, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26148, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26148, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26148, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26148, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26148, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26148, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26148, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26148, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26148, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26148, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26148, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26148, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26148, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26148, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26148, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26148, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26148, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26148, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26148, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26148, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26148, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26143, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26143, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26143, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26143, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26143, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26143, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26143, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26143, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26143, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26143, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26143, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26143, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26143, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26143, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26143, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26143, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26143, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26143, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26143, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26143, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26143, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26143, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26143, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26143, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(23015, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(23015, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(23015, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(23015, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(23015, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(23015, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(23015, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(23015, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(23015, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(23015, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(23015, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(23015, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(23015, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(23015, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(23015, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(23015, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(23015, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(23015, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(23015, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(23015, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(23015, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(19926, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(19926, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(19926, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(19926, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(19926, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(19926, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(19926, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(19926, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(19926, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(19926, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(19926, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(19926, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(19926, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(19926, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(19926, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(19926, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(19926, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(19926, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(19926, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(19926, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(19926, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(19926, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(19926, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(19926, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26146, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26146, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26146, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26146, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26146, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26146, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26146, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26146, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26146, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26146, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26146, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26146, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26146, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26146, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26146, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26146, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26146, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26146, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26146, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26146, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26146, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26146, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26146, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26146, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26133, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26133, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26133, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26133, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26133, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26133, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26133, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26133, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26133, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26133, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26133, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26133, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26133, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26133, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26133, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26133, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26133, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26133, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26133, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26133, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26133, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26133, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26133, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26133, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26130, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26130, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26130, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26130, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26130, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26130, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26130, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26130, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26130, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26130, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26130, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26130, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26130, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26130, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26130, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26130, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26130, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26130, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26130, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26130, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26130, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26130, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26130, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26130, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(25085, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(25085, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(25085, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25085, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(25085, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(25085, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25085, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(25085, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25085, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(25085, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(25085, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25085, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(25085, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(25085, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(25085, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(25085, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(25085, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25085, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(25085, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(25085, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(25085, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(25085, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25085, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(25085, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26120, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26120, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26120, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26120, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26120, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26120, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26120, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26120, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26120, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26120, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26120, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26120, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26120, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26120, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26120, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26120, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26120, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26120, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26120, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26120, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26120, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26120, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26120, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26120, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(5027, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(5027, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(5027, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(5027, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(5027, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(5027, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(5027, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(5027, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(5027, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(5027, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(5027, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(5027, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(5027, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(5027, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(5027, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(5027, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(5027, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(5027, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(5027, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(5027, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(5027, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(25083, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(25083, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(25083, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25083, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(25083, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(25083, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25083, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(25083, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25083, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(25083, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(25083, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25083, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(25083, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(25083, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(25083, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(25083, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(25083, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25083, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(25083, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(25083, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(25083, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(25083, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25083, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(25083, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26132, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26132, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26132, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26132, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26132, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26132, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26132, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26132, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26132, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26132, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26132, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26132, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26132, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26132, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26132, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26132, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26132, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26132, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26132, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26132, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26132, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26132, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26132, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26132, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(26119, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(26119, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26119, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26119, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(26119, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(26119, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(26119, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(26119, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26119, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26119, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26119, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(26119, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26119, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(26119, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(26119, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(26119, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(26119, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26119, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(26119, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(26119, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(26119, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(26119, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26119, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26119, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(25091, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(25091, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(25091, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25091, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(25091, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(25091, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25091, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(25091, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25091, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(25091, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(25091, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25091, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(25091, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(25091, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(25091, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(25091, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(25091, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25091, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(25091, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(25091, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(25091, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(25091, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25091, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(25091, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(25082, 'drug_class', 'N/A', 'minor', 'Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors: (see WARNINGS).', 'DailyMed'),
(25082, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(25082, 'glycopyrrolate', 'N/A', 'minor', 'Concomitant administration of Glycopyrrolate Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25082, 'folic acid, ferrous fumarate, ascorbic acid, cholecalciferol, .alpha.-tocopherol acetate, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, zinc oxide, cupric sulfate anhydrous, and selenomethionine', 'N/A', 'minor', 'Drugs which may interact with vitamin B12: Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B12.', 'DailyMed'),
(25082, 'methaver', 'N/A', 'minor', 'Drug s which may interact with vitamin B12:• Antibiotic, cholestyramine, colchicines, colestipol, metformin, para-amino salicylic acid, and potassium chloride may decrease the absorption of vitamin B12.• Nitro us oxide can produce a functional vitamin B12 deficiency.', 'DailyMed'),
(25082, 'robinul', 'N/A', 'minor', 'Concomitant administration of ROBINUL Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.', 'DailyMed'),
(25082, 'iron', 'N/A', 'minor', '7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production.', 'DailyMed'),
(25082, 'dobutamine hydrochloride', 'N/A', 'minor', 'Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25082, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(25082, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(25082, 'dobutamine', 'N/A', 'minor', 'There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.', 'DailyMed'),
(25082, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(25082, 'hyoscyamine sulfate', 'N/A', 'minor', 'Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride.', 'DailyMed'),
(25082, 'potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Other Products that Cause Hyperkalemia Administration of Potassium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, cyclosporine and tacrolimus) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia (see WARNINGS ). Avoid use of Potassium Chloride injection in patients receiving such products. Other Drugs that Increase the Risk of Hyponatremia Administration of Potassium Chloride Injection in patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatrem', 'DailyMed'),
(25082, 'glycopyrrolate orally disintegrating tablets', 'N/A', 'minor', '7 DRUG INTERACTIONS Concomitant use is not recommended with: Other Anticholinergic Drugs (5.3, 5.4, 5.6, 7.1) Drugs with Altered Absorption due to Decreased GI Motility (7.2) GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride. 7.3 Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time leading to prolonged contact with the gastrointestinal mucosa. DARTISLA ODT is not recommended in patients taking solid oral dosage forms of potassium chloride.', 'DailyMed'),
(25082, 'glycopyrrolate oral solution', 'N/A', 'contraindicated', 'The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see Contraindications (4)].', 'DailyMed'),
(25082, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25082, 'potassium chloride, dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in 5% Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in 5% Dextrose Injection can affect glycemic control, vasopressin an', 'DailyMed'),
(25082, 'dextrose and potassium chloride', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in 5% Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and flui', 'DailyMed'),
(25082, 'prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule', 'N/A', 'minor', 'Drugs which may interact with vitamin B 12 (Methylcobalamin): • Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic, and potassium chloride may decrease the absorption of vitamin B 12.', 'DailyMed'),
(25082, 'potassium chloride and dextrose monohydrate', 'N/A', 'contraindicated', '(7.2) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose Injection in patients receiving such products. 7.2 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Potassium Chloride in Dextrose Injection can affect glycemic control, vasopressin and fluid a', 'DailyMed'),
(25082, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25082, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(25082, 'dextrose monohydrate, sodium chloride, sodium lactate, potassium chloride, calcium chloride', 'N/A', 'contraindicated', '(7.2) • Digoxin: Consider reducing the volume or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7.4) 7.1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angi', 'DailyMed'),
(4440, 'drug_class', 'N/A', 'minor', 'Drug Interactions Since ethosuximide may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (e.g., ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).', 'DailyMed'),
(18605, 'drug_class', 'N/A', 'minor', 'Drug Interactions Since ethosuximide may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (e.g., ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).', 'DailyMed'),
(26307, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(26307, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9068, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(9068, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25890, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25890, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3614, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(3614, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3613, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(3613, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25892, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25892, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25886, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25886, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25885, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25885, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(22980, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(22980, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25898, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25898, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9069, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(9069, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(22981, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(22981, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(22982, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(22982, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19895, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(19895, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25891, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25891, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(3612, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(3612, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25889, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25889, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25899, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25899, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(19897, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(19897, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25888, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25888, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26306, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(26306, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(22201, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(22201, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(25887, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(25887, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(26305, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed'),
(26305, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(9070, 'chloramphenicol', 'N/A', 'minor', 'The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(9070, 'olanzapine', 'N/A', 'minor', 'Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.', 'DailyMed'),
(27155, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27155, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27155, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27155, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27155, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27155, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27155, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27155, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27155, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27155, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27155, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27155, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27155, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27155, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27155, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27155, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27155, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27155, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27155, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27155, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27155, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27155, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27155, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27155, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27155, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27155, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27155, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27155, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27155, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27155, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27155, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27155, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27155, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27155, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27155, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27155, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27155, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24749, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(24749, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(24749, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(24749, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24749, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24749, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(24749, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24749, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(24749, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(24749, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(24749, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24749, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(24749, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(24749, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24749, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(24749, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24749, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(24749, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24749, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(24749, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(24749, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(24749, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(24749, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(24749, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(24749, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(24749, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(24749, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24749, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24749, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(24749, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(24749, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24749, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(24749, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24749, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24749, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24749, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(24749, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26140, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26140, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26140, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26140, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26140, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26140, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26140, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26140, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26140, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26140, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26140, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26140, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26140, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26140, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26140, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26140, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26140, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26140, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26140, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26140, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26140, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26140, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26140, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26140, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26140, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26140, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26140, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26140, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26140, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27180, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27180, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27180, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27180, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27180, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27180, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27180, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27180, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27180, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27180, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27180, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27180, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27180, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27180, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27180, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27180, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27180, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27180, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27180, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27180, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27180, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27180, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27180, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27180, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27180, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27180, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27180, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27180, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27180, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27180, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27180, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27180, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27180, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27180, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27180, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27180, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27180, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24451, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(24451, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24451, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(24451, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24451, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(24451, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24451, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(24451, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24451, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(24451, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(24451, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24451, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(24451, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(24451, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(24451, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(24451, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(24451, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(24451, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(24451, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(24451, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24451, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(24451, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24451, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(24451, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24451, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24451, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24451, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(24451, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27200, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27200, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27200, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27200, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27200, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27200, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27200, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27200, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27200, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27200, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27200, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27200, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27200, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27200, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27200, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27200, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27200, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27200, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27200, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27200, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27200, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27200, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27200, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27200, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27200, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27200, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27200, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27200, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27200, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27200, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27200, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27200, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27200, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27200, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27200, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27200, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27200, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27195, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27195, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27195, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27195, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27195, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27195, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27195, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27195, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27195, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27195, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27195, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27195, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27195, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27195, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27195, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27195, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27195, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27195, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27195, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27195, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27195, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27195, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27195, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27195, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27195, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27195, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27195, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27195, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27195, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27195, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27195, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27195, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27195, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27195, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27195, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27195, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27195, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(2816, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(2816, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(2816, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(2816, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(2816, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(2816, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(2816, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(2816, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(2816, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(2816, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(2816, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(2816, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(2816, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(2816, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(2816, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(2816, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(2816, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(2816, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(2816, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(2816, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(2816, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(2816, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(2816, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(2816, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(2816, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(2816, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(2816, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(2816, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(2816, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(2816, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(2816, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(2816, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(2816, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(2816, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27140, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27140, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27140, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27140, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27140, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27140, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27140, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27140, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27140, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27140, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27140, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27140, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27140, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27140, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27140, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27140, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27140, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27140, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27140, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27140, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27140, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27140, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27140, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27140, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27140, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27140, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27140, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27140, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27140, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27140, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27140, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27140, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27140, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27140, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27140, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27140, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27140, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(15983, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(15983, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(15983, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(15983, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(15983, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(15983, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(15983, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(15983, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(15983, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(15983, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(15983, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(15983, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(15983, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(15983, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(15983, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(15983, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(15983, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(15983, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(15983, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(15983, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(15983, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(15983, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(15983, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(15983, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(15983, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(15983, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(15983, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(15983, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(15983, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(15983, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(15983, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(15983, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(15983, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(15983, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(15983, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(15983, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(15983, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(22625, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(22625, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(22625, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(22625, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(22625, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(22625, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(22625, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(22625, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(22625, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(22625, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(22625, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(22625, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(22625, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(22625, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(22625, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(22625, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(22625, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(22625, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(22625, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(22625, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(22625, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(22625, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(22625, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(22625, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(22625, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(22625, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(22625, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(22625, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(22625, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27206, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27206, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27206, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27206, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27206, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27206, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27206, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27206, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27206, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27206, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27206, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27206, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27206, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27206, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27206, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27206, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27206, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27206, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27206, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27206, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27206, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27206, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27206, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27206, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27206, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27206, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27206, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27206, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27206, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27206, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27206, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27206, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27206, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27206, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27206, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27206, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27206, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(15316, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(15316, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(15316, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(15316, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(15316, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(15316, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(15316, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(15316, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(15316, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(15316, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(15316, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(15316, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(15316, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(15316, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(15316, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(15316, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(15316, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(15316, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(15316, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(15316, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(15316, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(15316, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(15316, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(15316, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(15316, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(15316, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(15316, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(15316, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(15316, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(15316, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(15316, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(15316, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(15316, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(15316, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(15316, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(15316, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(15316, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26479, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(26479, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(26479, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26479, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26479, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26479, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26479, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26479, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26479, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(26479, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(26479, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26479, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(26479, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26479, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26479, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26479, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26479, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26479, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26479, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26479, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26479, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26479, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26479, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26479, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26479, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26479, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26479, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(26479, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26479, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26479, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(26479, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26479, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26479, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26479, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26479, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26479, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26479, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23020, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(23020, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23020, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23020, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(23020, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23020, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(23020, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23020, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(23020, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23020, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(23020, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(23020, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23020, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(23020, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(23020, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(23020, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(23020, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(23020, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23020, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(23020, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(23020, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23020, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(23020, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23020, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(23020, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23020, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23020, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23020, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(23020, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23271, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(23271, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(23271, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23271, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23271, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(23271, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23271, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(23271, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23271, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(23271, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(23271, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23271, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(23271, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(23271, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(23271, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23271, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(23271, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(23271, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(23271, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(23271, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(23271, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23271, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(23271, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(23271, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(23271, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23271, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(23271, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(23271, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23271, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(23271, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23271, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23271, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23271, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(23271, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(20163, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(20163, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(20163, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(20163, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(20163, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(20163, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(20163, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(20163, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(20163, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(20163, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(20163, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(20163, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(20163, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(20163, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(20163, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(20163, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(20163, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(20163, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(20163, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(20163, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(20163, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(20163, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(20163, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(20163, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(20163, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(20163, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(20163, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(20163, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(20163, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27165, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27165, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27165, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27165, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27165, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27165, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27165, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27165, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27165, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27165, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27165, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27165, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27165, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27165, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27165, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27165, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27165, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27165, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27165, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27165, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27165, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27165, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27165, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27165, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27165, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27165, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27165, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27165, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27165, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27165, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27165, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27165, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27165, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27165, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27165, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27165, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27165, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27183, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27183, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27183, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27183, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27183, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27183, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27183, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27183, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27183, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27183, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27183, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27183, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27183, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27183, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27183, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27183, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27183, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27183, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27183, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27183, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27183, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27183, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27183, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27183, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27183, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27183, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27183, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27183, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27183, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27183, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27183, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27183, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27183, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27183, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27183, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27183, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27183, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(25882, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(25882, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(25882, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(25882, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(25882, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(25882, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(25882, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(25882, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(25882, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(25882, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(25882, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(25882, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(25882, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(25882, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(25882, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(25882, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25882, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(25882, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(25882, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(25882, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(25882, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(25882, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(25882, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(25882, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(25882, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(25882, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(25882, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(25882, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(25882, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(25882, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(25882, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(25882, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(25882, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(25882, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(25882, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(25882, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(25882, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26135, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26135, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26135, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26135, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26135, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26135, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26135, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26135, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26135, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26135, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26135, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26135, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26135, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26135, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26135, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26135, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26135, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26135, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26135, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26135, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26135, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26135, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26135, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26135, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26135, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26135, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26135, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26135, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26135, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(6292, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(6292, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(6292, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(6292, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(6292, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(6292, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(6292, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(6292, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(6292, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(6292, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(6292, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(6292, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(6292, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(6292, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(6292, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(6292, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(6292, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(6292, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(6292, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(6292, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(6292, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(6292, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(6292, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(6292, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(6292, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(6292, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(6292, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(6292, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(6292, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(25737, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(25737, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(25737, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(25737, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(25737, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(25737, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(25737, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(25737, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(25737, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(25737, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(25737, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(25737, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(25737, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(25737, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(25737, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(25737, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(25737, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(25737, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(25737, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(25737, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(25737, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(25737, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(25737, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(25737, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(25737, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(25737, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(25737, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(25737, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(25737, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(7494, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(7494, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(7494, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(7494, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(7494, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(7494, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(7494, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(7494, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(7494, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(7494, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(7494, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(7494, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(7494, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(7494, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(7494, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(7494, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(7494, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(7494, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(7494, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(7494, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(7494, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(7494, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(7494, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(7494, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(7494, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(7494, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(7494, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(7494, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(7494, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17499, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(17499, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(17499, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17499, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17499, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17499, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17499, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17499, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17499, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(17499, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(17499, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17499, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(17499, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17499, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17499, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17499, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17499, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17499, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17499, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17499, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17499, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17499, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17499, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17499, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17499, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17499, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17499, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17499, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17499, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17499, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(17499, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17499, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17499, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17499, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17499, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17499, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17499, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26139, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26139, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26139, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26139, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26139, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26139, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26139, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26139, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26139, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26139, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26139, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26139, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26139, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26139, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26139, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26139, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26139, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26139, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26139, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26139, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26139, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26139, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26139, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26139, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26139, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26139, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26139, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26139, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26139, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23377, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(23377, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23377, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23377, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(23377, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23377, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(23377, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23377, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(23377, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23377, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(23377, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(23377, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23377, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(23377, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(23377, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(23377, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(23377, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(23377, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23377, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(23377, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(23377, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23377, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(23377, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23377, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23377, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23377, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23377, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23377, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(23377, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(10172, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(10172, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(10172, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(10172, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(10172, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(10172, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(10172, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(10172, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(10172, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(10172, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(10172, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(10172, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(10172, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(10172, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(10172, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(10172, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(10172, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(10172, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(10172, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(10172, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(10172, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(10172, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(10172, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(10172, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(10172, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(10172, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(10172, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(10172, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(10172, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(10172, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(10172, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(10172, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(10172, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(10172, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(10172, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(10172, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(10172, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(19890, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(19890, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(19890, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(19890, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(19890, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(19890, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(19890, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(19890, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(19890, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(19890, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(19890, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(19890, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(19890, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(19890, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(19890, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(19890, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(19890, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(19890, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(19890, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(19890, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(19890, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(19890, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(19890, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(19890, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(19890, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(19890, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(19890, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(19890, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(19890, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27177, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27177, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27177, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27177, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27177, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27177, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27177, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27177, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27177, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27177, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27177, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27177, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27177, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27177, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27177, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27177, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27177, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27177, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27177, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27177, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27177, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27177, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27177, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27177, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27177, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27177, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27177, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27177, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27177, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27177, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27177, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27177, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27177, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27177, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27177, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27177, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27177, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27188, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27188, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27188, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27188, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27188, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27188, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27188, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27188, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27188, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27188, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27188, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27188, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27188, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27188, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27188, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27188, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27188, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27188, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27188, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27188, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27188, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27188, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27188, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27188, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27188, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27188, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27188, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27188, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27188, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27188, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27188, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27188, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27188, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27188, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27188, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27188, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27188, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17486, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17486, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17486, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17486, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17486, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17486, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17486, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17486, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17486, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17486, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17486, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17486, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17486, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17486, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17486, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17486, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17486, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17486, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17486, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17486, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17486, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17486, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17486, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17486, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17486, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17486, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17486, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17486, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17486, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26915, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26915, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26915, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26915, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26915, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26915, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26915, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26915, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26915, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26915, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26915, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26915, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26915, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26915, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26915, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26915, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26915, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26915, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26915, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26915, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26915, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26915, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26915, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26915, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26915, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26915, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26915, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26915, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17491, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(17491, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(17491, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17491, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17491, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17491, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17491, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17491, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17491, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(17491, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(17491, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17491, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(17491, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17491, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17491, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17491, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17491, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17491, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17491, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17491, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17491, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17491, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17491, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17491, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17491, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17491, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17491, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17491, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17491, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17491, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(17491, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17491, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17491, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17491, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17491, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17491, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17491, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27204, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27204, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27204, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27204, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27204, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27204, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27204, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27204, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27204, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27204, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27204, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27204, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27204, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27204, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27204, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27204, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27204, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27204, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27204, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27204, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27204, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27204, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27204, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27204, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27204, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27204, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27204, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27204, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27204, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27204, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27204, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27204, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27204, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27204, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27204, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27204, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27204, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27174, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27174, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27174, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27174, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27174, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27174, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27174, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27174, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27174, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27174, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27174, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27174, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27174, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27174, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27174, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27174, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27174, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27174, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27174, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27174, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27174, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27174, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27174, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27174, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27174, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27174, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27174, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27174, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27174, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27174, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27174, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27174, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27174, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27174, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27174, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27174, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27174, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27151, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27151, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27151, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27151, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27151, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27151, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27151, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27151, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27151, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27151, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27151, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27151, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27151, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27151, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27151, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27151, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27151, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27151, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27151, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27151, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27151, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27151, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27151, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27151, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27151, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27151, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27151, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27151, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27151, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27151, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27151, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27151, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27151, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27151, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27151, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27151, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27151, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(7967, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(7967, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(7967, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(7967, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(7967, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(7967, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(7967, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(7967, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(7967, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(7967, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(7967, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(7967, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(7967, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(7967, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(7967, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(7967, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(7967, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(7967, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(7967, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(7967, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(7967, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(7967, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(7967, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(7967, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(7967, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(7967, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(7967, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(7967, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(7967, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(7967, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(7967, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(7967, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(7967, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(7967, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(7967, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(7967, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(7967, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(345, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(345, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(345, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(345, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(345, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(345, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(345, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(345, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(345, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(345, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(345, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(345, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(345, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(345, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(345, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(345, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(345, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(345, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(345, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(345, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(345, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(345, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(345, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(345, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(345, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(345, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(345, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(345, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(345, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(345, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(345, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(345, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(345, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(345, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(8792, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(8792, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(8792, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(8792, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(8792, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(8792, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(8792, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(8792, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(8792, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(8792, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(8792, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(8792, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(8792, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(8792, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(8792, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(8792, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(8792, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(8792, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(8792, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(8792, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(8792, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(8792, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(8792, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(8792, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(8792, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(8792, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(8792, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(8792, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(8792, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(8792, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(8792, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(8792, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(8792, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(8792, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(8792, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(8792, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(8792, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17498, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(17498, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(17498, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17498, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17498, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17498, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17498, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17498, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17498, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(17498, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(17498, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17498, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(17498, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17498, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17498, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17498, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17498, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17498, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17498, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17498, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17498, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17498, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17498, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17498, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17498, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17498, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17498, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17498, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17498, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17498, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(17498, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17498, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17498, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17498, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17498, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17498, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17498, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27152, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27152, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27152, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27152, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27152, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27152, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27152, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27152, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27152, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27152, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27152, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27152, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27152, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27152, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27152, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27152, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27152, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27152, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27152, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27152, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27152, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27152, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27152, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27152, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27152, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27152, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27152, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27152, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27152, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27152, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27152, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27152, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27152, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27152, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27152, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27152, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27152, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23719, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(23719, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(23719, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(23719, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23719, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23719, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(23719, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23719, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(23719, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(23719, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(23719, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23719, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(23719, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(23719, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23719, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(23719, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(23719, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(23719, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23719, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(23719, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(23719, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(23719, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(23719, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(23719, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23719, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(23719, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(23719, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(23719, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23719, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(23719, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(23719, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23719, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(23719, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23719, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23719, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23719, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(23719, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17459, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(17459, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(17459, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17459, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17459, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17459, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17459, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17459, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17459, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(17459, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(17459, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17459, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(17459, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17459, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17459, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17459, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17459, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17459, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17459, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17459, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17459, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17459, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17459, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17459, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17459, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17459, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17459, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17459, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17459, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17459, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(17459, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(17459, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17459, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17459, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17459, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17459, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17459, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23016, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(23016, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23016, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(23016, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(23016, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23016, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(23016, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23016, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(23016, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23016, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(23016, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(23016, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(23016, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(23016, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(23016, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(23016, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(23016, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(23016, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23016, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(23016, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(23016, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(23016, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(23016, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23016, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(23016, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(23016, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(23016, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(23016, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(23016, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17494, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(17494, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(17494, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17494, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17494, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17494, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17494, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17494, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17494, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(17494, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(17494, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17494, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(17494, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17494, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17494, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17494, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17494, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17494, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17494, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17494, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17494, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17494, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17494, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17494, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17494, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17494, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17494, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17494, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17494, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17494, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(17494, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17494, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17494, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17494, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17494, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17494, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17494, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26127, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26127, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26127, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26127, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26127, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26127, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26127, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26127, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26127, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26127, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26127, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26127, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26127, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26127, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26127, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26127, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26127, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26127, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26127, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26127, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26127, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26127, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26127, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26127, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26127, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26127, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26127, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26127, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26127, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17467, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(17467, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(17467, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17467, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17467, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17467, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17467, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17467, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17467, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(17467, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(17467, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17467, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(17467, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17467, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17467, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17467, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17467, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17467, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17467, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17467, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17467, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17467, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17467, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17467, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17467, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17467, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17467, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17467, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17467, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17467, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(17467, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17467, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17467, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17467, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17467, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17467, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17467, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(16811, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(16811, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(16811, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(16811, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(16811, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(16811, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(16811, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(16811, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(16811, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(16811, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(16811, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(16811, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(16811, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(16811, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(16811, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(16811, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(16811, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(16811, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(16811, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(16811, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(16811, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(16811, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(16811, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(16811, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(16811, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(16811, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(16811, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(16811, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(16811, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(16811, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(16811, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(16811, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(16811, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(16811, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(16811, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(16811, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(16811, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26121, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26121, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26121, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26121, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26121, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26121, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26121, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26121, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26121, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26121, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26121, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26121, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26121, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26121, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26121, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26121, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26121, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26121, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26121, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26121, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26121, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26121, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26121, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26121, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26121, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26121, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26121, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26121, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26121, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27141, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27141, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27141, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27141, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27141, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27141, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27141, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27141, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27141, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27141, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27141, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27141, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27141, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27141, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27141, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27141, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27141, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27141, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27141, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27141, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27141, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27141, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27141, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27141, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27141, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27141, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27141, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27141, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27141, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27141, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27141, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27141, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27141, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27141, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27141, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27141, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27141, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(19641, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(19641, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(19641, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(19641, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(19641, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(19641, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(19641, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(19641, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(19641, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(19641, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(19641, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(19641, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(19641, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(19641, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(19641, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(19641, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(19641, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(19641, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(19641, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(19641, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(19641, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(19641, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(19641, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(19641, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(19641, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(19641, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(19641, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(19641, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(19641, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(19641, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(19641, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(19641, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(19641, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(19641, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(19641, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(19641, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(19641, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24765, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(24765, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(24765, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(24765, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24765, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24765, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(24765, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24765, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(24765, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(24765, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(24765, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24765, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(24765, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(24765, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24765, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(24765, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24765, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(24765, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24765, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(24765, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(24765, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(24765, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(24765, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(24765, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(24765, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(24765, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(24765, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(24765, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24765, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(24765, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(24765, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24765, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(24765, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24765, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24765, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24765, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(24765, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27162, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27162, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27162, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27162, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27162, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27162, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27162, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27162, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27162, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27162, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27162, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27162, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27162, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27162, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27162, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27162, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27162, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27162, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27162, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27162, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27162, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27162, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27162, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27162, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27162, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27162, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27162, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27162, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27162, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27162, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27162, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27162, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27162, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27162, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27162, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27162, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27162, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(9580, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(9580, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(9580, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(9580, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(9580, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(9580, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(9580, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(9580, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(9580, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(9580, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(9580, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(9580, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(9580, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(9580, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(9580, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(9580, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(9580, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(9580, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(9580, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(9580, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(9580, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(9580, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(9580, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(9580, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(9580, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(9580, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(9580, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(9580, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(9580, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24301, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(24301, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24301, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(24301, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(24301, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24301, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(24301, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24301, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(24301, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24301, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(24301, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(24301, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(24301, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(24301, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(24301, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(24301, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(24301, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(24301, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(24301, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(24301, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(24301, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(24301, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(24301, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24301, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(24301, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(24301, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(24301, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(24301, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(24301, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27171, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27171, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27171, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27171, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27171, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27171, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27171, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27171, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27171, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27171, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27171, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27171, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27171, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27171, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27171, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27171, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27171, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27171, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27171, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27171, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27171, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27171, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27171, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27171, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27171, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27171, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27171, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27171, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27171, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27171, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27171, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27171, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27171, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27171, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27171, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27171, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27171, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26137, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(26137, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26137, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(26137, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(26137, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26137, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(26137, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26137, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(26137, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26137, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(26137, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(26137, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(26137, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(26137, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(26137, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(26137, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(26137, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(26137, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(26137, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(26137, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(26137, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(26137, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(26137, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26137, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(26137, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(26137, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(26137, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(26137, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(26137, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27157, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27157, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27157, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27157, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27157, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27157, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27157, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27157, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27157, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27157, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27157, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27157, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27157, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27157, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27157, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27157, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27157, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27157, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27157, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27157, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27157, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27157, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27157, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27157, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27157, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27157, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27157, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27157, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27157, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27157, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27157, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27157, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27157, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27157, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27157, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27157, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27157, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(32138, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(32138, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(32138, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(32138, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(32138, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(32138, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(32138, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(32138, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(32138, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(32138, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(32138, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(32138, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(32138, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(32138, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(32138, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(32138, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(32138, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(32138, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(32138, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(32138, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(32138, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(32138, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(32138, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(32138, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(32138, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(32138, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(32138, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(32138, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(32138, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(32138, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(32138, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(32138, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(32138, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(32138, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(32138, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(32138, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(32138, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27196, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27196, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27196, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27196, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27196, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27196, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27196, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27196, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27196, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27196, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27196, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27196, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27196, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27196, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27196, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27196, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27196, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27196, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27196, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27196, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27196, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27196, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27196, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27196, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27196, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27196, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27196, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27196, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27196, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27196, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27196, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27196, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27196, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27196, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27196, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27196, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27196, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(10173, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(10173, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(10173, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(10173, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(10173, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(10173, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(10173, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(10173, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(10173, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(10173, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(10173, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(10173, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(10173, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(10173, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(10173, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(10173, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(10173, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(10173, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(10173, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(10173, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(10173, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(10173, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(10173, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(10173, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(10173, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(10173, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(10173, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(10173, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(10173, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(10173, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(10173, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(10173, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(10173, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(10173, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(10173, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(10173, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(10173, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17489, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(17489, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(17489, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17489, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17489, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17489, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17489, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17489, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17489, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(17489, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(17489, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17489, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(17489, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17489, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17489, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17489, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17489, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17489, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17489, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17489, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17489, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17489, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17489, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17489, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17489, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17489, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17489, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17489, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17489, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17489, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(17489, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17489, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17489, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17489, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17489, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17489, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17489, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(14842, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(14842, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(14842, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(14842, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(14842, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(14842, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(14842, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(14842, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(14842, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(14842, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(14842, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(14842, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(14842, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(14842, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(14842, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(14842, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(14842, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(14842, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(14842, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(14842, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(14842, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(14842, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(14842, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(14842, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(14842, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(14842, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(14842, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(14842, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(14842, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(20140, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(20140, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(20140, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(20140, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(20140, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(20140, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(20140, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(20140, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(20140, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(20140, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(20140, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(20140, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(20140, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(20140, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(20140, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(20140, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(20140, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(20140, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(20140, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(20140, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(20140, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(20140, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(20140, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(20140, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(20140, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(20140, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(20140, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(20140, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(20140, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27138, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27138, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27138, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27138, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27138, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27138, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27138, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27138, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27138, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27138, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27138, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27138, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27138, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27138, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27138, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27138, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27138, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27138, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27138, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27138, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27138, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27138, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27138, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27138, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27138, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27138, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27138, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27138, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27138, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27138, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27138, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27138, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27138, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27138, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27138, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27138, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27138, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17482, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(17482, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(17482, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(17482, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17482, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(17482, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(17482, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17482, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(17482, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(17482, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(17482, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17482, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(17482, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(17482, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17482, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(17482, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17482, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(17482, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(17482, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(17482, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(17482, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(17482, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(17482, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(17482, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17482, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(17482, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(17482, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(17482, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(17482, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(17482, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(17482, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17482, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(17482, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(17482, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(17482, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(17482, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(17482, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27167, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27167, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27167, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27167, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27167, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27167, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27167, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27167, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27167, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27167, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27167, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27167, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27167, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27167, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27167, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27167, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27167, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27167, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27167, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27167, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27167, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27167, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27167, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27167, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27167, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27167, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27167, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27167, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27167, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27167, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27167, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27167, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27167, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27167, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27167, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27167, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(27167, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(4779, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(4779, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(4779, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(4779, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(4779, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(4779, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(4779, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(4779, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(4779, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(4779, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(4779, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(4779, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(4779, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(4779, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(4779, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(4779, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(4779, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(4779, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(4779, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(4779, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(4779, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(4779, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(4779, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(4779, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(4779, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(4779, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(4779, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(4779, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(4779, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(4779, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(4779, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(4779, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(4779, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(4779, 'hetastarch', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(4779, 'vasopressin in 0.9% sodium chloride', 'N/A', 'minor', '7 DRUG INTERACTIONS •Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) •Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(4779, 'piperacillin and tazobactam and sodium chloride', 'N/A', 'major', '7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (7.1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7.2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury.', 'DailyMed'),
(4779, 'potassium phosphates in sodium chloride', 'N/A', 'contraindicated', '(5.3, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27145, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.Use aseptic technique for single or multiple entry and withdrawal from all containers.When diluting or dissolving drugs, mix thoroughly and use promptly.Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.', 'DailyMed'),
(27145, 'polyethylene glycol-3350, sodium chloride, potassium chloride and sodium bicarbonate', 'N/A', 'minor', 'Drug Interactions Oral medication administered within one hour of the start of administration of PEG-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBONATE may be flushed from the gastrointestinal tract and not absorbed.', 'DailyMed'),
(27145, 'tranexamic acid', 'N/A', 'moderate', '7.1 Prothrombotic Medical Products Avoid concomitant use of Tranexamic Acid in Sodium Chloride Injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3)]. 7.2 Chlorpromazine Concurrent use of chlorpromazine and Tranexamic Acid in Sodium Chloride Injectionmay result in increased risk of bleeding.', 'DailyMed'),
(27145, 'sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27145, '0.9% sodium chloride', 'N/A', 'moderate', 'DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.', 'DailyMed'),
(27145, '3% sodium chloride', 'N/A', 'moderate', 'Drug Interactions Caution must be exercised in the administration of 3% Sodium Chloride Injection to patients treated with drugs that may increase the risk of sodium and fluid retention, such as corticosteroids. Renal sodium and lithium clearance may be increased during the administration of 3% Sodium Chloride Injection. Administration of 3% Sodium Chloride Injection may, therefore, result in decreased lithium levels.', 'DailyMed'),
(27145, 'dextrose monohydrate, sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance 2.5% Dextrose and 0.45% Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using 2.5% Dextrose and 0.45% Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of 2.5% Dextrose and 0.45% Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed'),
(27145, 'nitroglycerin', 'N/A', 'minor', 'More generally, nitroglycerin in 5% dextrose or sodium chloride 0.9% should not be mixed with any other medication of any kind.', 'DailyMed'),
(27145, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate, potassium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes ( 7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly ( 7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for or', 'DailyMed'),
(27145, 'polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride - unflavored', 'N/A', 'moderate', '7 DRUG INTERACTIONS Some drugs increase risks due to fluid and electrolyte changes (7.1) Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2) 7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities Use caution when prescribing polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. 7.2 Potential for Altered Drug Absorption Oral medication administered within one hour of the start of administration of polyethylene glycol 3350, sodium chloride, sodium bicarbonate', 'DailyMed'),
(27145, 'norepinephrine in sodium chloride', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27145, 'peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid', 'N/A', 'moderate', '(7.1) 7.1 Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. Consider additional patient evaluations as appropriate 7.2 Potential for Reduced Drug Absorption PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution can reduce the absorption of other co-', 'DailyMed'),
(27145, 'argatroban', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Heparin If Argatroban in sodium chloride injection is to be initiated after cessation of heparin therapy, allow sufficient time for heparin’s effect on the aPTT to decrease prior to initiation of Argatroban in sodium chloride injection therapy. 7.2 Oral Anticoagulant Agents Pharmacokinetic drug-drug interactions between Argatroban in sodium chloride injection and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban in sodium chloride injection and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5), Clinical Pharmacology (12.2)].', 'DailyMed'),
(27145, '6% hetastarch in 0.9% sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS 6% Hetastarch in 0.9% Sodium Chloride Injection should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.', 'DailyMed'),
(27145, 'vincristine sulfate', 'N/A', 'minor', 'It should not be mixed with anything other than 0.9% Sodium Chloride Injection USP.', 'DailyMed'),
(27145, 'sodium chloride and potassium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27145, 'calcium gluconate', 'N/A', 'moderate', 'Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration.', 'DailyMed'),
(27145, 'norepinephrine bitartrate', 'N/A', 'severe', '(7.4) 7.1 MAO-Inhibiting Drugs Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7.2 Tricyclic Antidepressants Co-administration of Norepinephrine Bitartrate in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension.', 'DailyMed'),
(27145, 'dexmedetomidine hydrochloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.', 'DailyMed'),
(27145, 'esmolol hydrochloride in sodium chloride', 'N/A', 'moderate', '7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility and impulse propagation. Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approxim', 'DailyMed'),
(27145, 'sodium chloride 0.9% w/v for intravenous infusion', 'N/A', 'moderate', 'Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.', 'DailyMed'),
(27145, 'pantoprazole sodium in 0.9% sodium chloride', 'N/A', 'contraindicated', 'Clinically Relevant Interactions Affecting Drugs Co-Administered with Pantoprazole Sodium in 0.9% Sodium Chloride Injection and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with pantoprazole sodium in 0.9% sodium chloride injection is contraindicated [see Contraindications (4)]. Nelfinavir: Avoid concomitant use with pantoprazole sodium in 0.9% sodium chloride injection See prescribing information for nelfinavir.', 'DailyMed'),
(27145, 'micafungin in sodium chloride', 'N/A', 'minor', '(7) 7.1 Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. Co-administration of Micafungin in Sodium Chloride Injection with Other Drugs Co-administration of Micafungin in Sodium Chloride Injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin.', 'DailyMed'),
(27145, 'fluconazole', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27145, 'daptomycin in sodium chloride', 'N/A', 'minor', 'Experience with the coadministration of HMG-CoA reductase inhibitors and daptomycin for injection in patients is limited; therefore, consideration should be given to suspending use of HMG-CoA reductase inhibitors temporarily in patients receiving Daptomycin in Sodium Chloride Injection. If confronted with an abnormally high PT/INR result in a patient being treated with Daptomycin in Sodium Chloride Injection, it is recommended that clinicians: 1.Repeat the assessment of PT/INR, requesting that the specimen be drawn just prior to the next Daptomycin in Sodium Chloride Injection dose (i.e., at trough concentration).', 'DailyMed'),
(27145, 'dexmedetomidine hydrochloride in 0.9% sodium chloride', 'N/A', 'minor', 'Reduction in dosage of dexmedetomidine hydrochloride in 0.9% sodium chloride injection or the concomitant medication may be required. (7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine hydrochloride in 0.9% sodium chloride injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects. No pharmacokinetic interactions between dexmedetomidine hydrochloride in 0.9% sodium chloride injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.', 'DailyMed'),
(27145, 'potassium chloride and sodium chloride', 'N/A', 'contraindicated', 'Drug Interactions Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Sodium Chloride Injection, USP and result in decreased lithium concentrations. Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Sodium Chloride Injection, USP in patients treated concurrently or recently with products that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. Avoid use of Potassium Chloride in Sodium Chloride Injection, USP in patients receiving such products (e.g., potassium sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the immunosuppressants cyclosporine and ', 'DailyMed'),
(27145, 'potassium phosphates', 'N/A', 'contraindicated', '(5.2, 7.1) 7.1 Other Products that Increase Serum Potassium Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products.', 'DailyMed'),
(27145, 'epinephrine', 'N/A', 'minor', '7 DRUG INTERACTIONS •Drugs that counter the pressor effects of Epinephrine in 0.9% Sodium Chloride Injection include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. (7.1) •Drugs that potentiate the effects of Epinephrine in 0.9% Sodium Chloride Injection include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (7.2) •Drugs that increase the arrhythmogenic potential of Epinephrine in 0.9% Sodium Chloride Injection include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides.', 'DailyMed'),
(27145, 'potassium chloride, dextrose monohydrate and sodium chloride', 'N/A', 'contraindicated', '(7.3) 7.1 Other Products that Cause Hyperkalemia Administration of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients treated concurrently or recently with other products that can cause hyperkalemia or increase the risk of hyperkalemia (e.g., potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.2)]. Avoid use of Potassium Chloride in Dextrose and Sodium Chloride Injection in patients receiving such products. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Potassium Chloride in Dextrose and Sodium Chloride Injection ', 'DailyMed'),
(27145, 'vasopressin', 'N/A', 'minor', '7 DRUG INTERACTIONS Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. (7.1) Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin in Sodium Chloride Injection on cardiac index and systemic vascular resistance.', 'DailyMed'),
(27145, 'nicardipine hydrochloride', 'N/A', 'moderate', 'Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine hydrochloride in sodium chloride injection. (7.3, 7.4) 7.1 Beta-Blockers In most patients, Nicardipine hydrochloride in sodium chloride injection can safely be used concomitantly with beta blockers. However, titrate slowly when using Nicardipine hydrochloride in sodium chloride injection in combination with a beta-blocker in heart failure patients [see Warnings and Precautions (5.2)].', 'DailyMed'),
(27145, 'dextrose and sodium chloride', 'N/A', 'moderate', '(7.2) 7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance Dextrose and Sodium Chloride Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.2, 5.3, 5.4, 5.5, 5.6)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose and Sodium Chloride Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance. 7.2 Lithium Renal sodium and lithium clearance may be increased during administration of Dextrose and Sodium Chloride Injection resulting in decreased serum lithium concentrations.', 'DailyMed');

